Asian Journal of Medicine and Health

Objective: The present study assesses clinician preferences, treatment patterns, and clinical experiences in the management of overactive bladder (OAB), with a special focus on the use of mirabegron in Indian clinical settings.

Methods: This cross-sectional study utilized a structured questionnaire to gather expert opinion from clinicians involved in OAB management across Indian settings. Twenty-six experienced clinical practitioners were one-on-one interviewed, responding to 23 questions that covered treatment preferences, management challenges, patient adherence, and experiences with mirabegron therapy.

Results: The survey included 26 clinicians and revealed that 77% preferred mirabegron as their primary choice for OAB management. Half of the respondents rated mirabegron's effectiveness as 4 out of 5 for symptom control. Approximately 77% preferred silodosin as the combination agent. Nearly 35% reported superior improvement in micturition frequency with mirabegron compared to antimuscarinics. Most clinicians (73.08%) recommended a minimum treatment duration of three months. For nocturia-predominant cases, nearly 65% preferred mirabegron. Tolerability was favorable, with 46% observing that 60–80% of patients continued therapy over one year. Around 77% of clinicians preferred switching to mirabegron when solifenacin failed to provide adequate relief.

Conclusion: This study highlights a strong clinician preference for mirabegron in OAB management, supported by its perceived superior tolerability, effectiveness in nocturia, and utility both as a first-line therapy and as an alternative when antimuscarinics fail. These findings are consistent with existing evidence supporting mirabegron’s role in comprehensive OAB treatment strategies.